Currently, luliconazole is confirmed to be sued topically in the therapy of dermatophytosis. Besides, it also has invitro activity against some molds and yeast species. A recent study assessed the efficacy of luliconazole compared with the regularly used antifungals on clinical and environmental isolates of Aspergillus flavus.

The results of the study revealed that luliconazole had the highest in vitro activity against A. flavus strains. The study findings showed that luliconazole with extremely low minimum inhibitory concentration range, 0.00049-0.00781 and MICGM 0.00288 µg/mL exhibited strong activity against clinical and environmental A. flavus isolates. On the contrary, all the isolates were reported to be resistant to amphotericin B.

Luliconazole is a synthetic imidazole antifungal; firstly, synthesized by Nihon Nohyaku Co. Ltd in Japan in 2005 and similar to other common azoles. It is effective on ergosterol biosynthesis with lesser adverse reactions and high potency. Initially, it was available as topical cream 1% for dermatophytosis and solution 105 for onychomycosis. Earlier, a very low minimum inhibitory concentration of luliconazole for dermatophytes, Candida, Fusarium, and Aspergillus species was reported.

Reference: Moslem M, Mahmoudabadi AZ. The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains. Iran J Microbial. 2020; 12(2): 170-176.